Adaptive Biotechnologies Corp
NASDAQ:ADPT
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
Market Cap | EV/EBITDA | ||||
---|---|---|---|---|---|
US |
Adaptive Biotechnologies Corp
NASDAQ:ADPT
|
419.3m USD | -0.4 | ||
US |
Thermo Fisher Scientific Inc
NYSE:TMO
|
223.7B USD | 23.1 | ||
US |
Danaher Corp
NYSE:DHR
|
184B USD | 26.2 | ||
US |
IQVIA Holdings Inc
NYSE:IQV
|
45.8B USD | 18 | ||
KR |
Samsung Biologics Co Ltd
KRX:207940
|
59.3T KRW | 36.5 | ||
US |
Agilent Technologies Inc
NYSE:A
|
42.9B USD | 27.9 | ||
CH |
Lonza Group AG
SIX:LONN
|
39.1B CHF | 29.6 | ||
US |
West Pharmaceutical Services Inc
NYSE:WST
|
29.1B USD | 33.5 | ||
US |
Mettler-Toledo International Inc
NYSE:MTD
|
28.9B USD | 25.4 | ||
IE |
ICON PLC
NASDAQ:ICLR
|
27.5B USD | 18.7 | ||
FR |
Sartorius Stedim Biotech SA
PAR:DIM
|
24.2B EUR | 39 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.